Guanhao Biotech Co.,Ltd. (SHE:300238)

Market Cap	3.98B +10.9%
Revenue (ttm)	387.75M +2.7%
Net Income	24.35M -11.2%
EPS	0.09 -10.0%
Shares Out	265.16M
PE Ratio	166.78
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,994,400
Average Volume	7,984,651
Open	15.34
Previous Close	15.34
Day's Range	14.93 - 15.42
52-Week Range	11.91 - 19.98
Beta	0.39
RSI	46.37
Earnings Date	Mar 26, 2026

About Guanhao Biotech

Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products in China. It offers NormalGEN and GrandNeuro, both a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; Type B dura, a spinal patch; Sterile Bio Wound Membrane; Ario Mesh; Thoracic Surgery Repair Diaphragm; and Cympic Benvimod Cream for psoriasis. In addit...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 535
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300238

Financial Performance

In 2025, Guanhao Biotech's revenue was 387.75 million, an increase of 2.72% compared to the previous year's 377.48 million. Earnings were 24.35 million, a decrease of -11.20%.